全文获取类型
收费全文 | 16351篇 |
免费 | 1079篇 |
国内免费 | 131篇 |
学科分类
医药卫生 | 17561篇 |
出版年
2024年 | 29篇 |
2023年 | 204篇 |
2022年 | 447篇 |
2021年 | 742篇 |
2020年 | 400篇 |
2019年 | 500篇 |
2018年 | 656篇 |
2017年 | 479篇 |
2016年 | 543篇 |
2015年 | 615篇 |
2014年 | 748篇 |
2013年 | 982篇 |
2012年 | 1404篇 |
2011年 | 1420篇 |
2010年 | 791篇 |
2009年 | 720篇 |
2008年 | 1202篇 |
2007年 | 1091篇 |
2006年 | 977篇 |
2005年 | 868篇 |
2004年 | 806篇 |
2003年 | 702篇 |
2002年 | 534篇 |
2001年 | 64篇 |
2000年 | 53篇 |
1999年 | 72篇 |
1998年 | 106篇 |
1997年 | 67篇 |
1996年 | 50篇 |
1995年 | 43篇 |
1994年 | 46篇 |
1993年 | 24篇 |
1992年 | 29篇 |
1991年 | 21篇 |
1990年 | 19篇 |
1989年 | 16篇 |
1988年 | 8篇 |
1987年 | 10篇 |
1986年 | 12篇 |
1985年 | 11篇 |
1984年 | 5篇 |
1983年 | 6篇 |
1982年 | 7篇 |
1981年 | 5篇 |
1980年 | 7篇 |
1979年 | 6篇 |
1978年 | 2篇 |
1977年 | 2篇 |
1974年 | 2篇 |
1966年 | 3篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
21.
Maria Rosaria Raspollini Gianni Amunni Alessandro Villanucci Francesca Castiglione Duccio Rossi Degl'Innocenti Gianna Baroni Milena Paglierani Gian Luigi Taddei 《Applied immunohistochemistry & molecular morphology》2006,14(2):181-186
The bcl-2 protein is a membrane protein involved in prolonging cell survival by inhibiting apoptosis. The HER-2 oncogene, which is located on chromosome 17 and encodes for a tyrosine-kinase growth factor receptor, is amplified and HER-2/neu is overexpressed in 25% to 30% of breast carcinomas. The authors analyzed the bcl-2 expression and the bcl-2 gene and HER-2/neu overexpression and amplification in FIGO stage IIIC, serous, G3, ovarian carcinomas obtained from living patients who had no evident disease 5 years after primary treatment compared with ovarian carcinomas obtained from patients, matched for stage, grade of differentiation, and treatment, who had died of progression of disease no later than 2 years after primary treatment. bcl-2 overexpression was statistically correlated with progression of disease during first-line chemotherapy (P=0.021). The HER-2/neu status was found not to correlate with progression of disease during first-line chemotherapy. Both bcl-2 and HER-2/neu expression were not statistically associated with the clinical outcome of ovarian cancer patients. Gene amplification of the HER-2/neu chromosome 17 was found in all the HER-2/neu, 3+ score, positive-staining ovarian carcinomas. None of the analyzed samples revealed a translocation t(14;18)(q32;q21) in the bcl-2 gene. The knowledge of additional prognostic or even predictive factors, such as bcl-2 expression, in patients with advanced ovarian carcinoma before the primary chemotherapeutic treatment may help in the management of patients who require a more tailored treatment. In addition, the gene amplification of the HER-2/neu suggests that HER-2 is a potential target for treatment in ovarian cancer. 相似文献
22.
Raspollini MR Castiglione F Garbini F Villanucci A Amunni G Baroni G Boddi V Taddei GL 《International journal of surgical pathology》2005,13(2):135-142
We analyzed in advanced ovarian serous G3 carcinoma the correlation between epidermal growth factor receptor (EGFR) overexpression and tumor angiogenesis and their relation with clinical outcome. Microvessel density (MVD) and vascular endothelial growth factor (VEGF) were statistically correlated with disease-free interval and death from disease both in univariate and multivariate analyses while EGFR expression was not correlated with clinical outcome. MVD was significantly associated with progression of disease during chemotherapy while VEGF and EGFR expression were not correlated with responsiveness to chemotherapy (Fisher's exact test). VEGF expression was correlated with MVD (Fisher's exact test). EGFR showed a trend to correlation with MVD. Further studies focusing on the use of angiogenesis inhibitors in addition to EGFR inhibitors on ovarian carcinoma cells may produce therapeutic strategies in the selection of tailored therapies in ovarian cancer patients. 相似文献
23.
Micci F Walter CU Teixeira MR Panagopoulos I Bjerkehagen B Saeter G Heim S 《Cancer Genetics and Cytogenetics》2003,144(2):119-124
Endometrial stromal sarcomas (ESS) are rare neoplasms with the capacity both to invade the myometrium locally and to give rise to extrauterine metastases. Cytogenetic abnormalities have been reported in 22 cases of ESS, mostly involving rearrangements of chromosomes 6, 7, and 17. The most characteristic translocation of this tumor type, t(7;17)(p15 approximately p21;q12 approximately q21), was recently shown to generate a JAZF1/JJAZ1 fusion gene. We report three additional cases of ESS with abnormal karyotypes, whose interpretation was based on the combined analysis by conventional cytogenetics and cross-species color banding FISH (RxFISH). The combination of G-banding and RxFISH in every case gave additional information beyond that obtained by either technique alone, determining the identity of even complex inter- as well as intrachromosomal rearrangements. In one of the three tumors, a t(7;17) was seen; molecular genetic studies identified the JAZF1/JJAZ1 fusion gene in this case. Two tumors had aberrations that included structural changes of chromosome arms 6p and 7p. Evidently, karyotypic, and hence pathogenetic, heterogeneity exists for tumors classified as endometrial stromal sarcomas based on their phenotypic features. 相似文献
24.
25.
Claudia Ciaccio Chiara Pantaleoni Donatella Milani Enrico Alfei Francesca L. Sciacca Laura Canafoglia Alessandra Erbetta Stefano D'Arrigo 《American journal of medical genetics. Part A》2020,182(10):2317-2324
Potocki–Lupski syndrome is a condition mainly characterized by infantile hypotonia, developmental delay/intellectual disability (DD/ID), and congenital anomalies, caused by duplications of the 17p11.2 region, encompassing RAI1 gene. Its clinical presentation is extremely variable, especially for what concerns the cognitive level and the behavioral phenotype. Such aspects, as well as the dysmorphic/malformative ones, have been covered by previous studies; otherwise neurological features have never been systematically described. In order to delineate the neurological phenotype of Potocki–Lupski Syndrome, we collect an 8‐patients cohort. Developmental milestones are delayed and a mild to moderate cognitive impairment is present in all patients, variably associated with features of autism spectrum disorder, behavioral disturb, and sleep disturb. Hypotonia appears a less frequent finding than what previously reported, while motor clumsiness/coordination impairment is frequent. EGG registration demonstrated a common pattern with excess of diffuse rhythmic activity in sleep phases or while the patient is falling asleep. Brain MRI did not reveal common anomalies, although unspecific white matter changes may be present. We discuss such findings and compare them to literature data, offering an overview on the neurological and cognitive‐behavioral presentation of the syndrome. 相似文献
26.
A kindred with MYH-associated polyposis and pilomatricomas 总被引:4,自引:0,他引:4
Baglioni S Melean G Gensini F Santucci M Scatizzi M Papi L Genuardi M 《American journal of medical genetics. Part A》2005,(2):212-214
MYH-associated polyposis (MAP) is a recently described autosomal recessive form of familial adenomatous polyposis (FAP) associated with susceptibility to colorectal carcinoma (CRC). MAP is caused by biallelic inactivating mutations of the MYH gene, a component of the base excision repair (BER) machinery, whose dysfunction leads to an increase in the rate of G > T transversions following DNA oxidative damage. MAP patients can present with either classic or attenuated polyposis. However, the MAP colonic and extracolonic phenotype has yet to be defined. We report on two siblings, born from consanguineous parents, who were found to be homozygotes for an MYH frameshift mutation. The propositus presented with a low number of colonic lesions and an early-onset CRC. Both siblings had a history of pilomatricomas, benign tumors derived from hair follicles, in childhood. The findings presented provide further evidence of phenotypic variability in MAP, and suggest that multiple pilomatricomas may be a useful cutaneous marker of MAP. 相似文献
27.
Ligand and cytokine dependence of the immunosuppressive pathway of tryptophan catabolism in plasmacytoid dendritic cells 总被引:3,自引:0,他引:3
Fallarino F Orabona C Vacca C Bianchi R Gizzi S Asselin-Paturel C Fioretti MC Trinchieri G Grohmann U Puccetti P 《International immunology》2005,17(11):1429-1438
Murine plasmacytoid dendritic cells (pDCs) have been credited with a unique ability to express indoleamine 2,3-dioxygenase (IDO) function and mediate immunosuppression in specific settings; yet, the conditions of spontaneous versus induced activity have remained unclear. We have used maneuvers known to up-regulate IDO in different cell types and have examined the relative efficacy and mechanisms of the induced activity in splenic pDCs, namely, after specific receptor engagement by CTLA-4-Ig, CD200-Ig or CD28-Ig, the latter in combination with silenced expression of the suppressor of cytokine signaling 3 (SOCS3) gene. We found that pDCs (CD11c+ mPDCA-1+ 120G8+) do not express IDO and are not tolerogenic under basal conditions. B7-1 engagement by CTLA-4-Ig, CD200R1 engagement by CD200-Ig and B7-1/B7-2 engagement by CD28-Ig in SOCS3-deficient pDCs were each capable of initiating IDO-dependent tolerance via different mechanisms. IFN-gamma was the major cytokine responsible for CTLA-4-Ig effects, and type I IFNs for those of CD200-Ig. Immunosuppression by CD28-Ig in the absence of SOCS3 required IFN-gamma induction and IFN-like actions of IL-6. Therefore, although pDCs do not mediate IDO-dependent tolerance constitutively, multiple ligands and cytokines will contribute to the expression of a tolerogenic phenotype by pDCs in the mouse. 相似文献
28.
29.
30.